Modeling and simulation of the endogenous CYP3A induction marker 4β-hydroxycholesterol during enasidenib treatment

BACKGROUND: Enasidenib (IDHIFA(®), AG-221) is a first-in-class, targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia. This was a Phase I/II study evaluating safety, efficacy, and pharmacokinetics/pharmacodynamics (PK/PD) of orally administered ena...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yan, Connarn, Jamie N, Chen, Jian, Tong, Zeen, Palmisano, Maria, Zhou, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385784/
https://www.ncbi.nlm.nih.gov/pubmed/30858735
http://dx.doi.org/10.2147/CPAA.S192687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385784/
https://www.ncbi.nlm.nih.gov/pubmed/30858735
http://dx.doi.org/10.2147/CPAA.S192687

Ejemplares similares